Author: Nicholas Caito

Michael Kinch – Cutting NIH budget could cripple drug development

Michael Kinch A proposal to slash funding for the National Institutes of Health (NIH) could severely impair the development of new, life-saving drugs, according to a new analysis by researchers at Washington University School of Medicine in St. Louis.

NIH funding supports the early research needed to develop new, innovative drugs. President Donald Trump’s proposed budget calls for cutting the NIH budget by 21 percent, or about $7.2 billion.
(more…)

Epidermal growth factor receptors containing a single tyrosine in their C-terminal tail bind different effector molecules and are signaling-competent.

Gill K., Macdonald-Obermann J.L., and Pike L.J.
Epidermal growth factor receptors containing a single tyrosine in their C-terminal tail bind different effector molecules and are signaling-competent.
J Biol Chem. pii: jbc.M117.802553. doi: 10.1074/jbc.M117.802553. (2017) (Abstract)

Multifunctional inhibitors of MET/RON signaling and cross-talk with EGFR/HER2

October 2nd, 2017 – Jim Janetka, PhD, Associate Professor of Biochemistry and Molecular Biophysics and Chemistry Adjunct received a two year, Career Catalyst Research (CCR) Competitive Renewal Grant Program award from Susan G. Komen for the Cure for his research entitled “Multifunctional inhibitors of MET/RON signaling and cross-talk with EGFR/HER2”. The work is focused on developing new drugs to treat breast cancer by dual targeting of the tumor and its microenvironment.